Long-term treatment of patients with HIV-1: the role of atazanavir

Long-term treatment of patients with HIV-1: the role of atazanavir

Blog Article

Miguel Ángel Artacho1, Pablo Barreiro2, José Vicente Fernández-Montero21Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, SpainBackground: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients.Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better bostik universal primer pro tolerance and convenience has been achieved in recent years.Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.Methods: Review of observational and randomized trials reported in medical conferences, 30hh bikini peer-reviewed journals, and treatment guidelines.

Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure.Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.Keywords: atazanavir, HAART, protease inhibitors.